That the drug will only be given to patients shown through testing to harbor a genetic anomaly that increases the odds of a response makes its approval an important milestone in the evolution of value-based care.
The test, which the company will sell directly to consumers, is designed to find whether patients metabolize drugs quickly or slowly.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The $8 per share deal will allow Illumina to tap into the long-read sequencing market, while also heading off competition from other firms, analyst writes.
Helix, based near San Francisco, touts its API-based business model as a way to stand out among the plethora of personal genomics companies.
Boston-based drugmaker Vertex Pharmaceuticals leads the round and also enters partnership with UK firm to aid its own drug development efforts.
Healthcare leaders have an opportunity to build their infrastructure right this time – with foresight into how valuable genomic data will be to all their stakeholders, now and into the future.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
People will be empowered through DNA if companies offer engaging and informative products built by innovative developers, powered by an advanced platform and delivered at the highest standards of quality and privacy.
St. Jude Cloud lets researchers view over 5,000 whole-genome, 5,000 whole-exome and 1,200 RNA-Seq datasets from more than 5,000 pediatric cancer patients and survivors.
There are over 70,000 genetic tests on the market and up to 10 new ones make an appearance every day. Many offer exciting prospects for healthcare, but numerous companies make claims such as being able to customize a diet to fit one's genomic profile or predicting the athletic abilities of one's children.
A recent study notes that widespread access to personal genetic information – without the knowledge of how to interpret results – can lead to problems ranging from misinterpretation to emotional distress.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The Food and Drug Administration has granted 23andMe the first-ever authorization for direct-to-consumer genetic testing for cancer risk without a prescription.
Distrust in genetic sequencing and medical testing abound, but the fact is that genomic medicine is a breakthrough tool for diagnosis and treatment.
This effort to boost healthcare entrepreneurs has combined investment in the Finnish healthcare startup community with initiatives at home and in the U.S. to foster the growth and development of the nation's healthcare ecosystem.
This year's finalists in the health and wellness track reflect not only the convergence between life sciences and health IT but also between sensors and smart textiles.
23andMe's weight loss study reflects the company's push to refine genomic tests by identifying genetic determinants of various diseases and chronic conditions. The study also dovetails with other companies that want to take on the country's weight management challenge with genetic testing.